William Blair analyst Brandon Vazquez has maintained their bullish stance on ISRG stock, giving a Buy rating yesterday.
Brandon Vazquez has given his Buy rating due to a combination of factors that highlight Intuitive Surgical’s strong performance and growth potential. The company’s first-quarter results exceeded expectations, with sales and earnings per share surpassing consensus estimates by 3% and 4%, respectively. This was driven by impressive global and international procedure growth rates, indicating robust demand for Intuitive’s offerings.
Despite macroeconomic challenges such as potential tariff impacts and uncertainties around Medicaid and capital expenditure budgets, Intuitive Surgical has shown resilience. The company’s strategic initiatives, including its operating lease strategy, are helping to mitigate these risks. Additionally, the appointment of a new head of cardiac surgery and the scheduled launch of the DV5 system in 2025, along with new software features, signal promising avenues for future growth. These factors collectively support Vazquez’s optimistic outlook on the stock.
In another report released yesterday, BTIG also maintained a Buy rating on the stock with a $542.00 price target.